Menu
Menu
gMendel
gMendel® combines genetics, AI and blockchain to provide better care for people with genetic disorders and rare diseases.
- AI, Blockchain, Female Founder, Healthtech
- Seed
Location
Copenhagen, Denmark
Revenue size
EUR 0 (pre-revenue)
Year founded
2020
Funding raised
EUR 1 million
Founders
Chris Kyriakidis, Zoran Velkoski, Hanna Pyokari
Most relevant investors
Danish Innovation Fund
Team size
18
Problem
Rare diseases and genetic disorders affect nearly 350 million families with children worldwide. The current clinical protocol does not provide accurate diagnoses (or none at all), due to prohibitive costs of advanced technologies and scarce expert knowledge. It takes approximately 7 years to make a diagnosis, and even then 40% of patients are misdiagnosed. This results in a heavy human, economic and societal burden, with lifetime costs surpassing €2.5M per person.
SOLUTION
By combining genomics, AI & blockchain, gMendel® provides a shorter, safer & more economical path to accurate diagnosis & potential treatment, ensuring the highest security & patient data encryption. Our solution provides the following features:
- An "end to end solution" from sample extraction to library preparation, sequencing, data analysis, feature extraction to assessment/diagnosis
- gMendel offers the only in vitro diagnostic certified technology with real-time data analysis of hundreds of samples with high accuracy and low cost.
- Data protection through blockchain technology.
- Higher margins by 30-50% to diagnostic labs.
KEY CUSTOMERS AND INTERNATIONAL PRESENCE
gMendel is working worldwide with leading universities, institutes and advocacy groups to ensure effective use of breakthrough technologies and fair access for all.
Our customers include: a) diagnostic labs; b) private/public hospitals; c) Ministries of Health; d) other health industry actors.
Team
Co-Founders Chris Kyriakidis and Zoran Velkoski both have been driven by personal experience, due to having family and friends who have suffered from genetic disorders and rare diseases.
They have built a strong team of 18, consisting of academics with PhDs in Machine learning, biochemistry, genetic sequencing, and experienced entrepreneurs, specialists, research and data scientists, to provide a high-quality product.
Unique selling point
gMendel is the only in vitro diagnostic certified technology that can perform simultaneous real-time data analysis on multiple samples. gMendel’s technology provides high accuracy at a low cost.
Asia Connection
gMendel is looking for investors and distribution partners across the East Asian region.
Pitch
